Spyglass Capital Management LLC Trims Stock Position in Medpace Holdings, Inc. $MEDP

Spyglass Capital Management LLC decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 32.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 150,882 shares of the company’s stock after selling 73,589 shares during the period. Medpace accounts for 4.1% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 13th largest holding. Spyglass Capital Management LLC owned about 0.54% of Medpace worth $77,577,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wasatch Advisors LP grew its holdings in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares during the last quarter. AQR Capital Management LLC grew its stake in Medpace by 15.1% during the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after buying an additional 81,637 shares during the last quarter. Baillie Gifford & Co. grew its stake in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after buying an additional 62,503 shares during the last quarter. Invesco Ltd. increased its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares during the period. Finally, Epoch Investment Partners Inc. increased its position in Medpace by 11.4% during the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after buying an additional 45,435 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of MEDP opened at $450.41 on Friday. The stock has a market capitalization of $12.78 billion, a P/E ratio of 29.44, a P/E/G ratio of 2.13 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The company’s fifty day moving average is $523.62 and its two-hundred day moving average is $538.46.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the previous year, the firm earned $3.67 earnings per share. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on MEDP. Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective for the company in a report on Friday, March 6th. Mizuho set a $582.00 price target on shares of Medpace in a research note on Wednesday, February 11th. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a research report on Tuesday, February 10th. Royal Bank Of Canada assumed coverage on shares of Medpace in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective on the stock. Finally, BMO Capital Markets restated a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.